Results 151 to 160 of about 579,513 (302)

Computational modelling of cardiac fibroblast signalling reveals a key role for Ca2+ in driving atrial fibrillation‐associated fibrosis

The Journal of Physiology, EarlyView.
Abstract figure legend A pre‐existing fibroblast signalling model was enhanced by integrating atrial‐specific components and reactions linked to atrial fibrosis and atrial fibrillation (AF). The analysis highlights the central role of Ca2⁺ signalling in driving profibrotic responses to AF‐relevant stimuli, angiotensin‐II and transforming growth factor ...
Najme Khorasani, Haibo Ni, Jeffrey J Saucerman, Dobromir Dobrev, Stefano Morotti, Eleonora Grandi   +5 more
wiley   +1 more source

Subtherapeutic Warfarin Is Not Associated With Increased Hemorrhage Rates in Ischemic Strokes Treated With Tissue Plasminogen Activator

Stroke, 2011
J. Cameron, A. Cheung, D. Streiner, P. Coyte, D. Stewart   +4 more
semanticscholar   +1 more source

One-Year Outcomes After Intravenous Recombinant Tissue Plasminogen Activator for Ischemic Stroke: A Real-World Study. [PDF]

CNS Neurosci Ther
Xue R, Gong X, Huang Y, Zhong W, Jin H, Chen Z, Chen Y, Yan S, Hu H, Yuan C, Lou M.   +10 more
europepmc   +1 more source

Management of submacular hemorrhage secondary to age-related macular degeneration with vitrectomy and subretinal tissue plasminogen activator injection: Outcomes and prognostic factors. [PDF]

SAGE Open Med
Li MM, Zhang H, Cen ZM, Su DW.
europepmc   +1 more source

Pathogenic PF4/Polyanion ELISA‐Negative Antibodies in HIT

American Journal of Hematology, Volume 101, Issue 8, Page 1790-1798, August 2026.
ABSTRACT Background Platelet factor 4‐polyanion enzyme‐linked immunosorbent assays (ELISAs) are considered highly sensitive for diagnosing heparin‐induced thrombocytopenia (HIT), such that current practice guidelines recommend use of ELISA‐negative results to exclude HIT.
Adam J. Kanack, Noah P. Splinter, Emily E. Mauch, Leben Tefera, Morayma Reyes Gil, Sakshi Jasra, Andrew Goodwin, Kristi J. Smock, Hadiyah Ahmad, Aneel Ashrani, Nathaniel L. Robinson, Ana I. Casanegra, Curtis G. Jones, Shannon M. Pechauer, Erin Yttre, Richard H. Aster, Mindy C. Kohlhagen, Rachel R. Leger, Gretchen Johns, David L. Murray, Lu Zhou, Demin Wang, Renren Wen, Dong Chen, Rajiv K. Pruthi, Anand Padmanabhan   +25 more
wiley   +1 more source

Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.

Journal of the American College of Cardiology, 1988
A. Rao, C. Pratt, A. Berke, A. Jaffe, I. Ockene, T. Schreiber, W. Bell, G. Knatterud, T. Robertson, M. Terrin   +9 more
semanticscholar   +1 more source

Intravenous tissue plasminogen activator in functional stroke mimics. [PDF]

Postep Psychiatr Neurol
Kowalska MM, Michałowska MM, Leńska-Mieciek MM.   +2 more
europepmc   +1 more source

The Immuno‐Cardiovascular Storm of Pre‐Eclampsia: Cytokine‐Mediated Endothelial Injury, Thrombosis, and Maternal Cardiovascular Instability

Comprehensive Physiology, Volume 16, Issue 4, August 2026.
Placental ischemia in pre‐eclampsia initiates cytokine‐driven endothelial dysfunction, angiogenic imbalance, oxidative stress, and thromboinflammation. Elevated TNF‐α, IL‐6, IL‐17, sFlt‐1, and complement activation promote vasoconstriction, thrombosis, and cardiovascular instability.
Emmanuel Ifeanyi Obeagu
wiley   +1 more source

Pharmaceutical Compatibility of Tissue Plasminogen Activator and DNase.

Respiration
Frencken JF, Hassanzai M, Hoek RAS, van der Sijs HH.   +3 more
europepmc   +1 more source

Successful Intraluminal Administration of Tissue Plasminogen Activator for Life-Threatening Obstructive Hematoma in Extremely Preterm Infants. [PDF]

J Korean Med Sci
Kim SH, Ahn SY, Kim H, Hwang J, Yang M, Sung SI, Chang YS.   +6 more
europepmc   +1 more source